US Stock MarketDetailed Quotes
INBX Inhibrx Biosciences
- 12.980
- -0.930-6.69%
Close Jul 18 16:00 ET
187.90MMarket Cap-1141P/E (TTM)
13.865High12.960Low186.07KVolume13.800Open13.910Pre Close2.47MTurnover2.34%Turnover RatioLossP/E (Static)14.48MShares18.95052wk High-17.45P/B103.16MFloat Cap12.61052wk Low--Dividend TTM7.95MShs Float18.950Historical High--Div YieldTTM6.51%Amplitude12.610Historical Low13.271Avg Price1Lot Size
Inhibrx Biosciences Key Stats
Quarterly+Annual
YOY
| (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q1)Mar 31, 2023 | (FY)Dec 31, 2022 | |
|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||
| Cash flow from continuing operating activities | -49.65%-40.31M | -42.06%-129.01M | -26.94M | -90.81M |
| Net income from continuing operations | -24.39%-49.27M | -34.37%-154.96M | ---39.61M | ---115.33M |
| Operating gains losses | ---- | 8,515.79%1.64M | --2K | --19K |
| Depreciation and amortization | 22.03%360K | -2.78%1.19M | --295K | --1.23M |
| Other non cash items | 8.90%465K | -91.92%131K | --427K | --1.62M |
| Change In working capital | -57.41%3.09M | -40.20%2.31M | --7.26M | --3.86M |
| -Change in receivables | 1,108.51%474K | -183.90%-521K | ---47K | --621K |
| -Change in prepaid assets | -2,636.17%-1.19M | -1,741.52%-6.68M | --47K | --407K |
| -Change in payables and accrued expense | -25.67%5.73M | 64.22%11.37M | --7.7M | --6.92M |
| -Change in other current assets | ---1.42M | --0 | --0 | ---1.32M |
| -Change in other current liabilities | -10.99%-495K | -11.11%-1.86M | ---446K | ---1.67M |
| -Change in other working capital | ---- | ---- | ---- | ---1.1M |
| Cash from discontinued investing activities | ||||
| Operating cash flow | -49.65%-40.31M | -42.06%-129.01M | ---26.94M | ---90.81M |
| Investing cash flow | ||||
| Cash flow from continuing investing activities | -4,765.22%-1.12M | -569.53%-4.59M | -23K | -686K |
| Net PPE purchase and sale | -4,765.22%-1.12M | -569.53%-4.59M | ---23K | ---686K |
| Cash from discontinued investing activities | ||||
| Investing cash flow | -4,765.22%-1.12M | -569.53%-4.59M | ---23K | ---686K |
| Financing cash flow | ||||
| Cash flow from continuing financing activities | 53.67%41.43M | 46.02%133.6M | 26.96M | 91.5M |
| Net other financing activities | 53.67%41.43M | 46.02%133.6M | --26.96M | --91.5M |
| Cash from discontinued financing activities | ||||
| Financing cash flow | 53.67%41.43M | 46.02%133.6M | --26.96M | --91.5M |
| Net cash flow | ||||
| Beginning cash position | --0 | --0 | --0 | --0 |
| End cash Position | --0 | --0 | --0 | --0 |
| Free cash flow | -53.67%-41.43M | -46.02%-133.6M | ---26.96M | ---91.5M |
| Currency Unit | USD | USD | USD | USD |
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg
